Odyssey Health reports positive Phase I MAD safety data for concussion drug PRV-002

Odyssey Health, Inc.

PRV-002 was safe and well tolerated in 8 healthy volunteers given five daily doses.
No severe adverse events; vital signs, EKG, and blood labs normal.
Pharmacokinetics showed linear dose-concentration relationship and no drug accumulation.
Safety Review Committee unanimously approved start of MAD Cohort II (higher dose).
Low blood levels suggest intranasal delivery may target brain directly with fewer side effects.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.